Human Von Willebrand Factor ELISA Kit(VWF) (RMEK-0153016)
Cat. No.: RMEK-0153016
Category: ELISA Kits
INQUIRY
1 x 96 tests
Human Von Willebrand Factor (VWF) in vitro ELISA kit is designed for the quantitative measurement of Human Von Willebrand Factor in plasma, serum, and cell culture supernatants. A Von Willebrand Factor specific antibody has been precoated onto 96-well plates and blocked. Standards or test samples are added to the wells and subsequently a Von Willebrand Factor specific biotinylated detection antibody is added and then followed by washing with wash buffer. Streptavidin-Peroxidase Conjugate is added and unbound conjugates are washed away with wash buffer. TMB is then used to visualize Streptavidin-Peroxidase enzymatic reaction. TMB is catalyzed by Streptavidin-Peroxidase to produce a blue color product that changes into yellow after adding acidic stop solution. The density of yellow coloration is directly proportional to the amount of Von Willebrand Factor captured in plate.
Product Features
| Species Reactivity | Human |
|---|---|
| Detection Method | Colorimetric |
| Assay Duration | Multiple steps standard assay |
| Assay Time | 5h 00m |
| Assay Type | Sandwich (quantitative) |
| Precision | Intra-Assay-Overall--5.6%; Inter-Assay-Overall--9.6% |
| Sensitivity | Sensitivity: 0.38 mIU/mL |
| Range | 0.625 mIU/mL - 40 mIU/mL |
| Sample Type | Cell culture supernatant, Plasma, Serum |
| Key Features | Sensitivity: 0.38 mIU/mL; Range: 0.625 mIU/mL - 40 mIU/mL; Sample type: Cell culture supernatant, Plasma, Serum; Detection method: Colorimetric; Assay type: Sandwich (quantitative); Reacts with: Human |
Target Information
| Target Symbol | Vwf |
|---|---|
| UniProt ID | P04275 |
| Biomarker of SCs/CSCs | Triple Negative Breast Cancer |
| Function | Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma. |
| Cellular Localization | Secreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules. |
| Domain | The von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules. |
| Post-transcriptional Modifications | All cysteine residues are involved in intrachain or interchain disulfide bonds.N- and O-glycosylated. |
| Involvement in Disease | Defects in VWF are the cause of von Willebrand disease (VWD). VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII. |
Storage & Shipping
| Storage | Store at 2-8°C |
|---|---|
| Shipping | Gel Packs |
| Stability | The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. |
For research use only. Not for clinical use.
